Oldgren et al. [56] found that dalteparin administration in patients with unstable CAD (n = 555) did not affect IL-6, C-Reactive Protein (CRP), and fibrinogen levels, although it reduced coagulation activity and mortality rate in long term, so it is concluded that these effects are not related to its anti-inflammatory properties. The gene discussed is CRP; the disease is coronary artery disorder.